GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:
-
2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
Fireside chat at 12:50 p.m. ET
New York, NY
-
Goldman Sachs 47
th
Annual Global Healthcare Conference
Wednesday, June 10, 2026
Fireside chat at 8:00 a.m. ET
Miami Beach, FL
A webcast of the fireside chats will be available via the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
[email protected]
Media Contact:
Real Chemistry
[email protected]
